Loading organizations...
§ Private Profile · 1700 Owens St, San Francisco, California, 94158, United States
Clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM).
Based in San Francisco, California, Braveheart Bio is a clinical-stage biotechnology company focused on developing novel therapeutics for hypertrophic cardiomyopathy and related cardiovascular conditions. The organization recently licensed its lead drug candidate, a selective myosin inhibitor known as BHB-1893, from Jiangsu Hengrui Pharmaceuticals for an upfront payment of $65 million as part of a broader agreement potentially valued at $1 billion. The enterprise intends to advance this acquired therapeutic asset into late-stage clinical trials starting in 2026 to address current gaps in the standard of care for heart disease patients. To support these extensive clinical development and commercialization efforts, the company secured $185 million in Series A financing led by prominent life sciences investors Andreessen Horowitz, Forbion, and OrbiMed, alongside participation from Enavate Sciences. Braveheart Bio was officially founded in 2024 by Travis Murdoch.
Braveheart Bio has raised $190.0M across 1 funding round.
Braveheart Bio has raised $190.0M in total across 1 funding round.
Braveheart Bio has raised $190.0M across 1 funding round. Most recently, it raised $190.0M Series A in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2025 | $190M Series A | — | Forbion, RA Capital, Andreessen Horowitz, Enavate Sciences, Frazier Life Sciences, OrbiMed | Announced |
Braveheart Bio is a late clinical-stage biotechnology company developing novel small-molecule therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions.[1][6] Its lead candidate, BHB-1893 (licensed as HRS-1893 from Hengrui Pharma), is a selective cardiac myosin inhibitor designed to reduce excessive heart muscle contraction, improving heart performance in patients with obstructive HCM (oHCM), a condition affecting about 1 in 500 people in the US.[1][2][6] The company serves patients with HCM, addressing unmet needs in a market where Bristol Myers Squibb's Camzyos is the first approved therapy, by aiming to establish a new standard of care through late-stage global trials.[1][4][5] Launched in 2025 with $185M in Series A funding from investors like Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences—plus a prior $75M licensing deal—Braveheart shows strong growth momentum, with Phase 1 data presented at ESC 2025 and plans for global Phase 3 trials.[1][2][3]
Braveheart Bio emerged in 2025 as a US-based stealth startup incorporated in Delaware, built around licensing HRS-1893 from China's Jiangsu Hengrui Pharmaceuticals in September 2025.[2][3][4] The deal granted exclusive global rights (excluding Greater China) for $65M upfront (half cash, half equity), plus $10M on tech transfer and up to $1.013B in milestones and royalties, reflecting a "NewCo model" trend where investors back startups on China-originated assets.[2][3][4] CEO Dr. Travis Murdoch, former leader of HI-Bio (acquired by Biogen), brings expertise in advancing clinical programs and company-building.[2][4] The company officially launched on November 5, 2025, with its $185M Series A to fund late-stage development, naming Chris Viehbacher (ex-Novartis CEO) as board chair—pivotal moments signaling rapid traction in cardio biotech.[1][5]
Braveheart rides the wave of China-US biotech dealmaking, where 19+ startups licensed China-discovered drugs in 2025 amid China's rapid clinical progress and US investors' appetite for de-risked assets.[4][5] Timing aligns with HCM market growth—post-Camzyos approval in 2022—fueled by genetic insights into myosin-driven pathology and demand for superior therapies from players like Cytokinetics and Edgewise.[4][6] Market forces favor Braveheart: HCM's prevalence (1 in 500), high unmet need for non-invasive options, and investor surge into cardio (e.g., $185M Series A) amid a shift from immune-oncology.[1][5] It influences the ecosystem by validating the NewCo model, accelerating global access to Chinese innovations, and challenging incumbents in a $10B+ potential market.[2][3][4]
Braveheart is primed to disrupt HCM treatment with BHB-1893's late-stage push, targeting global Phase 3 trials in 2026 backed by $260M+ war chest and elite backers.[1][5] Trends like AI-driven precision cardio, expanding HCM diagnostics, and more China out-licenses will shape its path, potentially yielding approval by 2028-2029 if data confirms differentiation.[2][4] Its influence may grow via partnerships or acquisition, much like Murdoch's prior Biogen exit, solidifying its role in transforming heart failure care from a bold Series A launch.[1][4]
Braveheart Bio has raised $190.0M in total across 1 funding round.
Braveheart Bio's investors include Forbion, RA Capital, Andreessen Horowitz, Enavate Sciences, Frazier Life Sciences, OrbiMed.